8-K: Pliant Therapeutics Reports Positive Phase 2a Trial Data and Provides Corporate Update

Pliant Therapeutics announced positive interim safety and efficacy data from its Phase 2a INTEGRIS-PSC trial and provided a corporate update along with fourth quarter 2023 financial results.

Summary

• Pliant Therapeutics reported positive interim 12-week safety and efficacy data from the Phase 2a INTEGRIS-PSC trial for bexotegrast in patients with primary sclerosing cholangitis (PSC).
• The 320 mg dose of bexotegrast was well tolerated over 12 weeks, with no drug-related severe or serious adverse events.
• Bexotegrast at the 320 mg dose reduced Enhanced Liver Fibrosis (ELF) scores and PRO-C3 levels, and showed improvements in hepatocyte function and bile flow compared to placebo at Week 12.
• The company is continuing enrollment in the BEACON-IPF Phase 2b trial for bexotegrast in patients with idiopathic pulmonary fibrosis (IPF), which is expected to enroll approximately 270 patients.
• A Phase 1 trial of PLN-101095 in solid tumors is enrolling, with preliminary data expected in late 2024.
• The muscular dystrophy program is on track for a regulatory filing in the first quarter of 2024.
• Research and development expenses for the fourth quarter of 2023 were $33.2 million, compared to $25.1 million in the prior-year quarter.
• General and administrative expenses were $13.9 million, compared to $14.3 million for the prior-year quarter.
• The net loss for the quarter was $41.1 million, compared to $35.1 million for the prior-year quarter.
• As of December 31, 2023, the company had $495.7 million in cash, cash equivalents, and short-term investments, which is expected to fund operations into the second half of 2026.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong clinical trial results, a solid cash position, and clear development plans. The positive data from the INTEGRIS-PSC trial is a significant driver of the high sentiment score.

Positives

• The 320 mg dose of bexotegrast showed positive safety and efficacy data in the INTEGRIS-PSC trial.
• Bexotegrast demonstrated improvements in key markers for PSC, including ELF scores, PRO-C3 levels, hepatocyte function, and bile flow.
• The company has a strong cash position of $495.7 million, expected to fund operations into the second half of 2026.
• The muscular dystrophy program is progressing as planned with a regulatory filing expected in the first quarter of 2024.

Negatives

• The company reported a net loss of $41.1 million for the fourth quarter of 2023, an increase from the $35.1 million loss in the prior-year quarter.
• Research and development expenses increased to $33.2 million, up from $25.1 million in the prior-year quarter.

Risks

• The company's future results are subject to risks and uncertainties related to the development and commercialization of its product candidates.
• There are risks associated with delays in ongoing or planned preclinical or clinical trials.
• The company is subject to the impact of current macroeconomic and marketplace conditions, including health epidemics and pandemics.
• The company relies on third parties for critical aspects of its development operations.
• There are risks inherent in the drug development process, including the accuracy of expense estimates and timing of development.
• The company may require additional financing in the future.

Future Outlook

The company expects its current cash position, along with funds available under the Oxford Loan Agreement, to be sufficient to fund operations into the second half of 2026. The company plans to advance the BEACON-IPF late-stage program, gain clarity on next steps for a late-stage PSC program, and provide updates on its early-stage portfolio.

Management Comments

• Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant Therapeutics, stated that the progress made in the fourth quarter of 2023 positions the company well for executing upon its 2024 milestones.
• He also highlighted the recent positive data from the INTEGRIS-PSC trial, which supports the late-stage development of bexotegrast in PSC.

Industry Context

This announcement is significant in the context of the biotechnology industry, particularly for companies focused on developing treatments for fibrotic diseases. The positive data from the INTEGRIS-PSC trial for bexotegrast could position Pliant Therapeutics as a leader in this space. The company's focus on multiple clinical programs, including IPF, PSC, solid tumors, and muscular dystrophy, demonstrates a broad approach to addressing unmet medical needs.

Comparison to Industry Standards

• The positive 12-week data for bexotegrast in PSC is encouraging, as many companies struggle to show efficacy in this difficult-to-treat disease. Companies such as Intercept Pharmaceuticals with Ocaliva have struggled to gain traction in PSC due to side effects and limited efficacy.
• The ongoing BEACON-IPF trial is a key program for Pliant, as IPF is a major market with significant unmet need. Competitors such as Boehringer Ingelheim with Ofev and Roche with Esbriet have established treatments, but there is still room for improvement.
• Pliant's cash runway into the second half of 2026 is a positive sign, as many biotech companies face funding challenges. This compares favorably to companies with shorter cash runways that may need to raise capital sooner.

Stakeholder Impact

• Shareholders are likely to react positively to the positive clinical trial data and the company's strong cash position.
• Employees may be encouraged by the progress of the company's clinical programs and the financial stability.
• Patients with fibrotic diseases may benefit from the development of new treatments.
• The company's suppliers and partners may see continued business opportunities.

Next Steps

• The company will continue enrollment in the BEACON-IPF Phase 2b trial.
• The company expects to release 24-week data from the 320 mg dose group of the INTEGRIS-PSC trial in mid-2024.
• The company expects to release preliminary data from the Phase 1 trial of PLN-101095 in solid tumors in late 2024.
• The company plans to file for first-in-human clinical studies in Duchenne muscular dystrophy (DMD) in the first quarter of 2024.

Key Dates

Keywords

bexotegrast, fibrotic diseases, idiopathic pulmonary fibrosis, primary sclerosing cholangitis, clinical trials, PLN-101095, PLN-101325, muscular dystrophy, biotechnology, drug development